Detailed narrative
DT120 ODT Development Strategy and Regulatory Alignment
Definium Therapeutics is positioning DT120 ODT (lysergide tartrate) as a best-in-class product for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). The company has engaged with the FDA under the breakthrough therapy designation program, reaching alignment on key aspects of its development and submission strategy. This aims to maximize the speed and efficiency of the NDA submission for DT120 ODT, contingent on positive trial readouts in 2026. The clinical program includes four pivotal Phase III studies: Voyage and Panorama for GAD, and Emerge and Ascend for MDD.
Clinical Trial Progress and Design
Emerge, the first pivotal MDD study, is fully enrolled with top-line data expected in late Q2 2026. Ascend, the second MDD study, has activated its first sites and anticipates first participant dosing by early Q2 2026, benefiting from operational efficiencies. For GAD, Voyage is approximately 80% enrolled with top-line data expected in early Q3 2026, and Panorama is rapidly progressing for a H2 2026 readout. Each pivotal study includes a 12-week double-blind, placebo-controlled Part A and a 40-week open-label extension Part B, with primary endpoints at week 6 for MDD (MADRS) and week 12 for GAD (HAM-A).
Voyage Study Sample Size Re-estimation Results
A blinded sample size re-estimation for the Voyage GAD study was completed, confirming no increase in the trial's sample size was required. The analysis revealed a model-based standard deviation of 6.7 points on the HAM-A and a non-evaluable rate of 10% among the first 100 participants completing week 12. These observations suggest the study's statistical power substantially exceeds the planned 90%, implying over 99% power to detect a 5-point difference and a minimum difference of less than 2 points for statistical significance if these nuisance parameters remain consistent.
Commercial Readiness and Market Approach
Definium is focused on impeccable commercial readiness for potential launches in GAD and MDD, having mapped the provider landscape and prioritized key states. The commercial vision is to deliver a 'high-touch white glove experience' for providers, extending the collaborative approach from clinical development. This includes robust infrastructure for REMS certification, regulatory requirements, operational integration, and reimbursement pathways. The company has assembled an experienced commercial leadership team to navigate complex launches.
DT402 Program for Autism Spectrum Disorder (ASD)
The company initiated a Phase II study of DT402, the R enantiomer of MDMA, in late 2025 for autism spectrum disorder (ASD). DT402 has shown promising prosocial effects and a potentially favorable tolerability profile, targeting core ASD symptoms, particularly social communication. Initial data from this single-dose open-label Phase IIa study, assessing early efficacy signals in up to 20 adult participants, is expected later in 2026. This program addresses a high unmet need, as there are no FDA-approved therapies specifically for these core symptoms.